 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
15 August 1995 | Volume 123 Issue 4 | Pages 241-249
Objective: To investigate whether concurrent administration of misoprostol reduces the occurrence of serious upper gastrointestinal complications, such as perforation, gastric outlet obstruction, or bleeding, in patients with rheumatoid arthritis who are receiving nonsteroidal anti-inflammatory drugs (NSAIDs).
Design: 6-month randomized, double-blind, placebo-controlled trial.
Setting: 664 clinical practices of family medicine, internal medicine, or rheumatology in the United States and Canada.
Patients: 8843 men and women (mean age, 68 years) receiving continuous therapy with any of 10 specified NSAIDs for control of symptoms of rheumatoid arthritis. Patients were enrolled between July 1991 and August 1993.
Intervention: Patients were randomly assigned to receive 200 µg of misoprostol or placebo four times a day.
Measurements: Development of serious upper gastrointestinal complications detected by clinical symptoms or findings (not by scheduled endoscopy).
Results: Serious upper gastrointestinal complications were reduced by 40% (odds ratio, 0.598 [95% CI, 0.364 to 0.982; P = 0.049]) among patients receiving misoprostol (25 of 4404 patients) compared with those receiving placebo (42 of 4439 patients). During the first month, more patients receiving misoprostol (20%) than placebo (15%) withdrew from the study, primarily because of diarrhea and related problems (P < 0.001). Risk factors for serious upper gastrointestinal complications were increasing age, history of peptic ulcer or bleeding, and cardiovascular disease. Patients with all four risk factors would have a 9% risk for a major complication in 6 months.
Conclusions: In older patients with rheumatoid arthritis, misoprostol reduced serious NSAID-induced upper gastrointestinal complications by 40% compared with placebo.
Author and Article Information
From the University of Washington, Seattle, Washington. Baylor College of Medicine, Houston, Texas. University of Pennsylvania, Philadelphia, Pennsylvania. Quintiles Transnational Corporation, Research Triangle Park, North Carolina. G.D. Searle & Company, Skokie, Illinois.
ARTICLE
Misoprostol Reduces Serious Gastrointestinal Complications in Patients with Rheumatoid Arthritis Receiving Nonsteroidal Anti-Inflammatory Drugs
A Randomized, Double-Blind, Placebo-Controlled Trial
Requests for Reprints: G. Steven Geis, MD, 4901 Searle Parkway (A-3E), Skokie, IL 60077.
Acknowledgments: The authors thank Marie Griffin, MD, MPH, and Kenneth Brandt, MD, for their critical review of the data for patients who had suspected gastrointestinal events; William A.T. Archambault Jr., PhD, and John C. Alexander, MD, for their suggestions regarding the manuscript; and the 664 participating physicians. A list of the names and cities of these physicians can be obtained by contacting the author.
Grant Support: By a grant from G.D. Searle & Co.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  P. Foley, S. Foley, T. Kinnaird, and R.A. Anderson Clinical review: gastrointestinal bleeding after percutaneous coronary intervention: a deadly combination QJM, June 1, 2008; 101(6): 425 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Hunt, D. Choquette, B. N. Craig, C. De Angelis, F. Habal, G. Fulthorpe, J. I. Stewart, A. G.G. Turpie, and P. Davis Approach to managing musculoskeletal pain: Acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs? Can Fam Physician, July 1, 2007; 53(7): 1177 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rostom, C. Dube, G. Lewin, A. Tsertsvadze, N. Barrowman, C. Code, M. Sampson, and D. Moher Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force Ann Intern Med, March 6, 2007; 146(5): 376 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.K.S. Ong, P. Lirk, C.H. Tan, and R.A. Seymour An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs Clin. Med. Res., March 1, 2007; 5(1): 19 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Rahme and H. Nedjar Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study Rheumatology, March 1, 2007; 46(3): 435 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Adebayo and I Bjarnason Is non-steroidal anti-inflammaory drug (NSAID) enteropathy clinically more important than NSAID gastropathy? Postgrad. Med. J., March 1, 2006; 82(965): 186 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. SPINK, S. BAHN, and R. GLICKMAN Clinical implications of cyclo-oxygenase-2 inhibitors for acute dental pain management: Benefits and risks J Am Dent Assoc, October 1, 2005; 136(10): 1439 - 1448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Saseen ASHP Therapeutic Position Statement on the Daily Use of Aspirin for Preventing Cardiovascular Events Am. J. Health Syst. Pharm., July 1, 2005; 62(13): 1398 - 1405. [Full Text] [PDF]
|
|
|
|
 |
|
 Taking stock of coxibs DTB, January 1, 2005; 43(1): 1 - 6. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Gregor Acid Suppression and Pneumonia: A Clinical Indication for Rational Prescribing JAMA, October 27, 2004; 292(16): 2012 - 2013. [Full Text] [PDF]
|
|
|
|
 |
|
 R. B Jacobsen and B. B. Phillips Reducing Clinically Significant Gastrointestinal Toxicity Associated with Nonsteroidal Antiinflammatory Drugs Ann. Pharmacother., September 1, 2004; 38(9): 1469 - 1481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lin, W. Zhang, A. Jones, and M. Doherty Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials BMJ, August 7, 2004; 329(7461): 324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Miura, A. Tatsuguchi, K. Wada, H. Takeyama, Y. Shinji, T. Hiratsuka, S. Futagami, K. Miyake, K. Gudis, Y. Mizokami, et al. Cyclooxygenase-2-regulated vascular endothelial growth factor release in gastric fibroblasts Am J Physiol Gastrointest Liver Physiol, August 1, 2004; 287(2): G444 - G451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dickman and J. Ellershaw For Discussion NSAIDs: gastroprotection or selective COX-2 inhibitor? Palliative Medicine, June 1, 2004; 18(4): 275 - 286. [Abstract] [PDF]
|
|
|
|
|
|
J. M. Pellissier, D. J. Watson, S. X. Kong, and W. L. Straus Cost-Effectiveness of Cyclooxygenase-2 Inhibitors in Chronic Arthritis Ann Intern Med, May 4, 2004; 140(9): 761 - 761. [Full Text] [PDF]
|
|
|
|
 |
|
 K D Brandt Non-surgical treatment of osteoarthritis: a half century of "advances" Ann Rheum Dis, February 1, 2004; 63(2): 117 - 122. [Full Text] [PDF]
|
|
|
|
 |
|
 C J Hawkey, J I Jones, C T Atherton, M M Skelly, J R Bebb, U Fagerholm, B Jonzon, P Karlsson, and I T Bjarnason Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans Gut, November 1, 2003; 52(11): 1537 - 1542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Layton, K. Hughes, S. Harris, and S. A. W. Shakir Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data Rheumatology, November 1, 2003; 42(11): 1332 - 1341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G S. Geis CLASS clarification: reaffirms the medical importance of the analyses and results BMJ, October 6, 2003; 327(7418): E143 - 144. [Full Text] [PDF]
|
|
|
|
|
|
I Bjarnason, K Takeuchi, and R Simpson NSAIDs: the Emperor's new dogma? Gut, September 1, 2003; 52(9): 1376 - 1378. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Man-Son-Hing and A. Laupacis Anticoagulant-Related Bleeding in Older Persons With Atrial Fibrillation: Physicians' Fears Often Unfounded Arch Intern Med, July 14, 2003; 163(13): 1580 - 1586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Russo, A. Capone, E. Attanasio, G. Baio, M. Di Martino, L. Degli Esposti, F. Marchetta, S. Buda, E. Degli Esposti, and L. Caprino Pharmacoutilization and costs of osteoarthritis: changes induced by the introduction of a cyclooxygenase-2 inhibitor into clinical practice Rheumatology, July 1, 2003; 42(7): 879 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Nurmohamed, W. F. Lems, A. Lanas, D. F. McKeogh, F. K.L. Chan, and D. Y. Graham Celecoxib versus Diclofenac and Omeprazole to Prevent Recurrent Ulcer Bleeding N. Engl. J. Med., June 12, 2003; 348(24): 2464 - 2466. [Full Text] [PDF]
|
|
|
|
|
|
C J Hawkey, L Laine, T Simon, H Quan, S Shingo, and J Evans Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study Gut, June 1, 2003; 52(6): 820 - 826. [Abstract] [Full Text]
|
|
|
|
 |
|
 N. M. Gajraj Cyclooxygenase-2 Inhibitors Anesth. Analg., June 1, 2003; 96(6): 1720 - 1738. [Full Text] [PDF]
|
|
|
|
|
|
B. M.R. Spiegel, L. Targownik, G. S. Dulai, and I. M. Gralnek The Cost-Effectiveness of Cyclooxygenase-2 Selective Inhibitors in the Management of Chronic Arthritis Ann Intern Med, May 20, 2003; 138(10): 795 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Layton, E. Heeley, K. Hughes, and S. A. W. Shakir Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data Rheumatology, May 1, 2003; 42(5): 622 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C J Hawkey and M J S Langman Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors Gut, April 1, 2003; 52(4): 600 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P Guignard, S. Couray-Targe, C. Colin, and G. Chamba Economic Impact of Pharmacists' Interventions with Nonsteroidal Antiinflammatory Drugs Ann. Pharmacother., March 1, 2003; 37(3): 332 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-C. Bae, M. Corzillius, K. M. Kuntz, and M. H. Liang Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis Rheumatology, January 1, 2003; 42(1): 46 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. K.L. Chan, L. C.T. Hung, B. Y. Suen, J. C.Y. Wu, K. C. Lee, V. K.S. Leung, A. J. Hui, K. F. To, W. K. Leung, V. W.S. Wong, et al. Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis N. Engl. J. Med., December 26, 2002; 347(26): 2104 - 2110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Pickard, G. T. Schumock, and J. E. Dalen Aspirin Use May Change Cost-effectiveness of COX-2 Inhibitors Arch Intern Med, December 9, 2002; 162(22): 2637 - 2639. [Full Text] [PDF]
|
|
|
|
|
|
M Dougados, B Dijkmans, M Khan, W Maksymowych, S. van der Linden, and J Brandt Conventional treatments for ankylosing spondylitis Ann Rheum Dis, November 1, 2002; 61(90003): iii40 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. El-Serag, D. Y. Graham, P. Richardson, and J. M. Inadomi Prevention of Complicated Ulcer Disease Among Chronic Users of Nonsteroidal Anti-inflammatory Drugs: The Use of a Nomogram in Cost-effectiveness Analysis Arch Intern Med, October 14, 2002; 162(18): 2105 - 2110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Courtney and M Doherty Key questions concerning paracetamol and NSAIDs for osteoarthritis Ann Rheum Dis, September 1, 2002; 61(9): 767 - 773. [Full Text] [PDF]
|
|
|
|
|
|
R.A. Sharma Translational medicine: targetting cyclo-oxygenase isozymes to prevent cancer QJM, May 1, 2002; 95(5): 267 - 273. [Full Text] [PDF]
|
|
|
|
|
|
M. Man-Son-Hing and A. Laupacis Balancing the Risks of Stroke and Upper Gastrointestinal Tract Bleeding in Older Patients With Atrial Fibrillation Arch Intern Med, March 11, 2002; 162(5): 541 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Langman Commentary: Peptic ulcer, Susser and Stein and the cohort phenomenon Int. J. Epidemiol., February 1, 2002; 31(1): 27 - 28. [Full Text] [PDF]
|
|
|
|
|
|
D. Y. Graham, N. M. Agrawal, D. R. Campbell, M. M. Haber, C. Collis, N. L. Lukasik, and B. Huang Ulcer Prevention in Long-term Users of Nonsteroidal Anti-inflammatory Drugs: Results of a Double-blind, Randomized, Multicenter, Active- and Placebo-Controlled Study of Misoprostol vs Lansoprazole Arch Intern Med, January 28, 2002; 162(2): 169 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Pisetsky and E. W. St.Clair Progress in the Treatment of Rheumatoid Arthritis JAMA, December 12, 2001; 286(22): 2787 - 2790. [Full Text] [PDF]
|
|
|
|
|
|
J M Seager and C J Hawkey ABC of the upper gastrointestinal tract: Indigestion and non-steroidal anti-inflammatory drugs BMJ, November 24, 2001; 323(7323): 1236 - 1239. [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Montori and G. H. Guyatt Intention-to-treat principle Can. Med. Assoc. J., November 1, 2001; 165(10): 1339 - 1341. [Full Text] [PDF]
|
|
|
|
|
|
J. Brock, A. Sauaia, D. Ahnen, W. Marine, W. Schluter, B. R. Stevens, J. D. Scinto, H. Karp, and D. Bratzler Process of Care and Outcomes for Elderly Patients Hospitalized With Peptic Ulcer Disease: Results From a Quality Improvement Project JAMA, October 24, 2001; 286(16): 1985 - 1993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H. MacLean Quality Indicators for the Management of Osteoarthritis in Vulnerable Elders Ann Intern Med, October 16, 2001; 135(8_Part_2): 711 - 721. [Full Text] [PDF]
|
|
|
|
|
|
R M Valori, C M Brown, P Strangeways, and M Bradburn Reducing community dyspepsia drug costs: a controlled trial Gut, October 1, 2001; 49(4): 495 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. FitzGerald and C. Patrono The Coxibs, Selective Inhibitors of Cyclooxygenase-2 N. Engl. J. Med., August 9, 2001; 345(6): 433 - 442. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Varga and A. Dickman Ibuprofen to rofecoxib: What does it all mean and what do I do now? American Journal of Hospice and Palliative Medicine, July 1, 2001; 18(4): 271 - 274. [Abstract] [PDF]
|
|
|
|
|
|
M. D. Fernandez, J. L. Z. Garcia, F. D. Garcia, S. Gupta, C. Bombardier, L. Laine, and A. Reicin Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen N. Engl. J. Med., May 3, 2001; 344(18): 1398 - 1399. [Full Text] [PDF]
|
|
|
|
 |
|
 N. J Talley Review: misoprostol, double dose H2 receptor antagonists, and proton pump inhibitors reduce GI ulcers in long term NSAID use Evid. Based Med., May 1, 2001; 6(3): 88 - 88. [Full Text] [PDF]
|
|
|
|
|
|
K S S Steen, W F Lems, J Aertsen, D Bezemer, and B A C Dijkmans Incidence of clinically manifest ulcers and their complications in patients with rheumatoid arthritis Ann Rheum Dis, May 1, 2001; 60(5): 443 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. A. Mardini and G. A. FitzGerald Selective Inhibitors of Cyclooxygenase-2: A Growing Class of Anti-Inflammatory Drugs Mol. Interv., April 1, 2001; 1(1): 30 - 38. [Abstract] [Full Text]
|
|
|
|
|
|
A A Shah, B Thjodleifsson, F E Murray, E Kay, M Barry, G Sigthorsson, H Gudjonsson, E Oddsson, A B Price, D J Fitzgerald, et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen Gut, March 1, 2001; 48(3): 339 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ince Guest Editorial: The Use of COX-2-Specific Inhibitors: Is It All Hype or Is It Evidence Based? J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2001; 56(3): 136M - 137. [Full Text]
|
|
|
|
|
|
R I Russell Non-steroidal anti-inflammatory drugs and gastrointestinal damage{---}problems and solutions Postgrad. Med. J., February 1, 2001; 77(904): 82 - 88. [Full Text]
|
|
|
|
|
|
C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis, R. Day, M. B. Ferraz, C. J. Hawkey, M. C. Hochberg, et al. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis N. Engl. J. Med., November 23, 2000; 343(21): 1520 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. T. Felson, R. C. Lawrence, M. C. Hochberg, T. McAlindon, P. A. Dieppe, M. A. Minor, S. N. Blair, B. M. Berman, J. F. Fries, M. Weinberger, et al. Osteoarthritis: New Insights. Part 2: Treatment Approaches Ann Intern Med, November 7, 2000; 133(9): 726 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Are {blacktriangledown}rofecoxib and {blacktriangledown}celecoxib safer NSAIDS? DTB, November 1, 2000; 38(11): 81 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. E M van Dieten, I. B C K.-d. Bos, M. W van Tulder, W. F Lems, B. A C Dijkmans, and M. Boers Systematic review of the cost effectiveness of prophylactic treatments in the prevention of gastropathy in patients with rheumatoid arthritis or osteoarthritis taking non-steroidal anti-inflammatory drugs Ann Rheum Dis, October 1, 2000; 59(10): 753 - 759. [Abstract] [Full Text]
|
|
|
|
|
|
F. E. Silverstein, G. Faich, J. L. Goldstein, L. S. Simon, T. Pincus, A. Whelton, R. Makuch, G. Eisen, N. M. Agrawal, W. F. Stenson, et al. Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial JAMA, September 13, 2000; 284(10): 1247 - 1255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Article
